Delcath Systems, Inc. (DCTH) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Delcath Systems, Inc. is an interventional oncology company focused on treating cancers primary or metastatic to the liver. Its lead product, the HEPZATO KIT, received FDA approval in August 2023 for uveal melanoma with hepatic metastases, with commercial use beginning in January 2024. The company also markets the CHEMOSAT hepatic delivery system in Europe.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Total Revenue | $11.2 million | $0.4 million | $22.1 million | $1.5 million |
| Gross Profit | $9.6 million | $0.3 million | $18.0 million | $1.1 million |
| Gross Margin | 85.4% | 69.4% | 81.6% | 69.6% |
| Operating Loss | ($1.3 million) | ($10.6 million) | ($15.4 million) | ($26.9 million) |
| Net Income (Loss) | $1.9 million | ($20.3 million) | ($23.0 million) | ($36.5 million) |
| Cash & Equivalents | $8.3 million | $12.7 million (Dec 2023) | Short-term investments: $5.7 million | |
| Operating Cash Flow | Used $17.7 million (YTD 2024) | |||
| Debt Obligations | Convertible notes: $2.0 million; Avenue Loan: Paid in full (Aug 2024) |
Material Changes vs. Prior Period
- Revenue Surge: Revenue increased 2,481% in Q3 2024 compared to Q3 2023, driven by the commercial launch of HEPZATO in the U.S. ($10.0 million) and growth in CHEMOSAT sales ($1.2 million).
- Profitability Shift: The company reported a net income of $1.9 million in Q3 2024, a significant turnaround from a net loss of $20.3 million in the same period last year. This was primarily due to a $3.0 million gain from the change in fair value of warrant liabilities.
- Debt Reduction: The company fully repaid its $20 million Avenue Venture Opportunities Fund term loan in August 2024, removing a significant interest burden and security interest on assets.
- Expense Management: R&D expenses decreased by 17% in Q3 2024 compared to Q3 2023, while SG&A expenses increased by 12% due to commercial launch activities.
Guidance, Outlook, and Risks
- Liquidity Concerns: Management has raised substantial doubt about the company's ability to continue as a going concern if site activation for HEPZATO is substantially delayed or revenue falls short of expectations. The company may need to raise additional capital.
- Capital Commitments: The company estimates $6.8 million in commitments for the next 12 months (payables, leases, settlements) plus $2.0 million in convertible note principal payments.
- Warrant Exercise: The company announced in October 2024 that it met the $10 million quarterly revenue trigger, activating a 21-day window for Tranche B Warrants. As of November 5, 2024, these warrants were fully exercised, generating approximately $25.0 million in cash proceeds.
- Clinical Outlook: The company plans to initiate studies for HEPZATO in other liver cancers (e.g., colorectal, neuroendocrine) in late 2024 or early 2025.
- Audit Independence: The company's auditor, Marcum LLP, notified the company of a potential independence conflict due to CBIZ's acquisition of Marcum. An unrelated third party was hired to reperform valuations to ensure audit integrity.
Investor Verification Checklist
- Warrant Proceeds: Verify the actual cash receipt of the ~$25 million from the Tranche B warrant exercises post-filing date.
- Going Concern Status: Assess whether the recent warrant proceeds resolve the "substantial doubt" regarding liquidity and the need for further financing.
- Revenue Sustainability: Monitor Q4 2024 revenue to determine if the $10 million quarterly run rate is sustainable without the one-time warrant valuation gain.
- Site Activation: Track the number of new facilities activating HEPZATO procedures to validate commercial growth assumptions.
- Convertible Notes: Confirm the status of the $2.0 million Rosalind Notes maturing in October 2024 (filing notes indicate payment was made on maturity).